Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22 First disclosure of a novel mechanism of action for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback